Form 4: BioLife Solutions Executive Karen A. Foster Reports Stock Grants

Karen A. Foster, Chief Quality and Operations Officer of BioLife Solutions, reports the acquisition of common stock grants as part of her compensation.

Summary

• Karen A. Foster, Chief Quality and Operations Officer at BioLife Solutions, filed a Form 4 on March 20, 2025, reporting changes in beneficial ownership of the company's stock.
• On March 18, 2025, Foster acquired 19,099 shares of common stock granted under the 2023 Omnibus Performance Incentive Plan, which vest 25% on the first anniversary and then quarterly over the next 12 quarters.
• Additionally, she acquired 29,711 shares of common stock granted under the 2013 Performance Incentive Plan, which vested at 175% based on the company's total shareholder return from January 1, 2023, to December 31, 2024, compared to its peers.
• Following these transactions, Foster directly owns 203,722 shares of BioLife Solutions common stock.

Sentiment

Score: 7

Explanation: The document indicates positive performance relative to peers, as evidenced by the 175% vesting of shares. This suggests a healthy company trajectory and aligns executive interests with shareholder value.

Positives

• The stock grants to a key executive suggest confidence in the company's future performance.
• The vesting schedule of the 2023 plan incentivizes long-term commitment from the executive.
• The vesting of shares under the 2013 plan at 175% indicates strong shareholder return performance relative to peers.

Industry Context

Stock grants are a common form of executive compensation in the biotech industry, aligning management's interests with those of shareholders. The vesting of shares based on performance metrics is also a standard practice to incentivize specific outcomes.

Comparison to Industry Standards

• Stock grants are a typical component of executive compensation packages in publicly traded companies, particularly in the biotech sector.
• Companies like Thermo Fisher Scientific and Danaher also utilize stock-based compensation to align executive incentives with shareholder value creation.
• The vesting schedule of 25% on the first anniversary followed by quarterly installments is a common vesting structure, similar to those used by companies like Illumina and Agilent Technologies.
• Performance-based vesting, as seen in the 2013 plan, is also a standard practice, often tied to metrics like revenue growth, EBITDA, or total shareholder return, mirroring practices at companies like Mettler Toledo.

Stakeholder Impact

• Shareholders may view the stock grants positively, as they align executive compensation with company performance.
• Employees may see the grants as a sign of the company's commitment to its leadership team.
• The vesting of shares based on shareholder return benefits shareholders.

Key Dates

Keywords

Form 4, Beneficial Ownership, Stock Grants, BioLife Solutions, BLFS, Karen A. Foster, Executive Compensation, Shareholder Return